ArticleTalanta2021
Rapid and quantitative detection of SARS-CoV-2 IgG antibody in serum using optofluidic point-of-care testing fluorescence biosensor.
Article in Talanta, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Nanoparticle-supported, rapid, digital quantification of neutralizing antibodies against SARS-CoV-2 variants.Biosensors & bioelectronics · 2025Article
- Rapid and accurate detection of SARS-CoV-2 spike protein by aptamer conformation change based on a reusable aptasensor.Mikrochimica acta · 2025Article
- Fast and Sensitive Detection of Anti-SARS-CoV-2 IgG Using SiOBiomolecules · 2024Article
- PET Foils Functionalized with Reactive Copolymers as Adaptable Microvolume ELISA Spot Array Platforms for Multiplex Serological Analysis of SARS-CoV-2 Infections.Sensors (Basel, Switzerland) · 2024Article
- Optical biosensors for diagnosis of COVID-19: nanomaterial-enabled particle strategies for post pandemic era.Mikrochimica acta · 2024Review
- Detection of SARS-CoV-2 S protein based on FRET between carbon quantum dots and gold nanoparticles.Heliyon · 2023Article
- Sensors for in situ monitoring of oral and dental health parameters in saliva.Clinical oral investigations · 2023Review
- Nano-biosensor for SARS-CoV-2/COVID-19 detection: methods, mechanism and interface design.RSC advances · 2023Review
- The SARS-CoV-2 specific IgG antibodies biophotonic sensor.Journal of biophotonics · 2023Article
- Colorimetric Detection of the SARS-CoV-2 Virus (COVID-19) in Artificial Saliva Using Polydiacetylene Paper Strips.Biosensors · 2022Article
- Progress in Biosensors for the Point-of-Care Diagnosis of COVID-19.Sensors (Basel, Switzerland) · 2022Review
- Review
- Human Body Performance with COVID-19 Affectation According to Virus Specification Based on Biosensor Techniques.Sensors (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The COVID-19 pandemic brings unprecedented crisis for public health and economics in the world. Detecting specific antibodies to SARS-CoV-2 is a powerful supplement for the diagnosis of COVID-19 and is important for epidemiological studies and vaccine validations. Herein, a rapid and quantitative detection method of anti-SARS-CoV-2 IgG antibody was built based on the optofluidic point-of-care testing fluorescence biosensor. Without complicated steps needed, the portable system is suitable for on-site sensitive determination of anti-SARS-CoV-2 IgG antibody in serum. Under the optimal conditions, the whole detection procedure is about 25 min with a detection limit of 12.5 ng/mL that can well meet the diagnostic requirements. The method was not obviously affected by IgM and serum matrix and demonstrated to have good stability and reliability in real sample analysis. Compared to ELISA test results, the proposed method exhibits several advantages including wider measurement range and easier operation. The method provides a universal platform for rapid and quantitative analysis of other related biomarkers, which is of significance for the prevention and control of COVID-19 pandemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.